Advertisement
Finance
Subscribe to Finance

The Lead

Soligenix Awarded $24.7M NIAID Contract to Develop Heat Stable RiVax Vaccine

September 19, 2014 8:11 am | News | Comments

The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been...

Elanco Animal Health, Dow AgroSciences Announce Strategic R&D Agreement

September 18, 2014 9:09 am | News | Comments

Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly...

Bayer to Split Off Polymer Division with IPO

September 18, 2014 7:45 am | by The Associated Press | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for...

View Sample

FREE Email Newsletter

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

Auxilium Pharma Board Adopts Anti-Takeover Plan

September 17, 2014 8:48 am | by The Associated Press | News | Comments

The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.   

EMD Serono and Sutro Biopharma Announce $298M Deal to Develop Antibody Drug Conjugates

September 17, 2014 8:14 am | News | Comments

EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

Advertisement

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

MedGenesis Enters Into Agreement with Pfizer for Potential Treatments for Parkinson's Disease

September 16, 2014 9:07 am | News | Comments

MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

Allergan Agrees to Move Forward with Meeting

September 16, 2014 6:44 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

Advertisement

NY Files Alzheimer's Drug Lawsuit

September 15, 2014 7:42 pm | by Michael Virtanen - Associated Press - Associated Press | News | Comments

New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.

Avanir Pharma Soars on Agitation Drug Study

September 15, 2014 3:46 pm | by The Associated Press | News | Comments

Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. The company said patients who were treated with AVP-923 were less agitated than patients given a placebo.

FDA Accepts Tuzistra XR NDA for Full Review

September 15, 2014 8:12 am | News | Comments

Vernalis and Tris Pharma announced that the FDA has confirmed that the New Drug Application for Tuzistra XR has been accepted for full review. This triggers a milestone payment from Vernalis to Tris.        

Gilead to License Generic Version of Sovaldi

September 15, 2014 8:07 am | by The Associated Press | News | Comments

Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.           

Livestrong Takes Hit after Armstrong Confession

September 12, 2014 8:19 am | by JIM VERTUNO, Associated Press | News | Comments

The Livestrong cancer charity is reporting a sharp drop in donations and revenue after founder Lance Armstrong admitted taking performance-enhancing drugs during most of his record-setting cycling career.        

Advertisement

Abbott Approves $3B Share Buyback

September 11, 2014 3:16 pm | News | Comments

Abbott Laboratories said Thursday that its board approved spending up to $3 billion to buy back the health conglomerate's stock.                     

Cellerant Awarded $47.5M Under Existing Contract to Support Development of CLT-008

September 11, 2014 8:59 am | News | Comments

The award will support the continued advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS).        

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

September 11, 2014 8:37 am | News | Comments

Baxter International has announced that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.             

Gates Foundation to Spend $50M on Ebola Response

September 10, 2014 2:49 pm | by DONNA GORDON BLANKINSHIP, Associated Press | News | Comments

The Seattle-based foundation said the money will go to the United Nations, the World Health Organization, the U.S. Centers for Disease Control and Prevention and international organizations involved in fighting transmission of the virus.  

PharmAthene Awarded Contract Of Up To $28.1M to Develop Next Generation Thermostable Anthrax Vaccine

September 10, 2014 9:12 am | News | Comments

PharmAthene announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded the company a contract, valued at up to $28.1M if all contract options are exercised, for the development of a next generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.

Seattle Genetics and Genmab Enter Into Antibody-Drug Conjugate Collaboration

September 10, 2014 8:25 am | News | Comments

Under the new agreement, Genmab will pay an upfront fee of $11M for exclusive rights to utilize Seattle Genetics' auristatin-based ADC technology with Genmab'sHuMax(R)-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers.

Auxilium Pharma to Cut Workforce by 30%

September 10, 2014 8:15 am | News | Comments

Auxilium Pharmaceuticals said Tuesday it is cutting 30 percent of its workforce, about 190 jobs, as part of a restructuring of its operations that will save it at least $75 million a year.           

China's Premier Promises More Open Economy

September 10, 2014 8:09 am | by JOE McDONALD, AP Business Writer | News | Comments

China's premier promised Wednesday to open the world's No. 2 economy wider to foreign companies, promising favorable conditions despite a wave of anti-monopoly investigations that business groups say might be aimed at limiting competition.

Mylan to Pay $300M for U.S. Rights to Arixtra Injection

September 10, 2014 7:59 am | News | Comments

Mylan has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated.

NY Judge Sentences Pharma ex-Trader to Nine Years in Prison

September 9, 2014 8:23 am | by LARRY NEUMEISTER, Associated Press | News | Comments

A former portfolio manager convicted of helping his firm earn more than a quarter-billion dollars illegally through insider trading on a promising Alzheimer's drug trial was sentenced Monday to nine years in prison by a judge who said lengthy incarceration was earned with a staggering fraud that was the biggest of its kind.

Merus Labs Acquire Sintrom from Novartis

September 8, 2014 8:49 am | News | Comments

Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).          

Ophthotech Achieves $50M Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®

September 8, 2014 8:07 am | News | Comments

Ophthotech Corporation today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading